T. Alanko

发表

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

K. Partanen, U. Gerdemann, A. Hemminki, 2012, Cancer research.

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

H. Joensuu, P. Kellokumpu-Lehtinen, K. Sunela, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Jorma Isola, Heikki Joensuu, Vesa Kataja, 2006, The New England journal of medicine.

FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes.

T. Alanko, O. Saksela, M. Rosenberg, 1999, The Journal of investigative dermatology.

S24 Update of the FINHER trial based on 5 years of follow-up

V. Kataja, J. Isola, H. Joensuu, 2009 .

Transforming growth factor beta1 induces apoptosis in normal melanocytes but not in nevus cells grown in type I collagen gel.

T. Alanko, O. Saksela, Olli Saksela, 2000, The Journal of investigative dermatology.

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

H. Isoniemi, T. Alanko, P. Bono, 2014, OncoTargets and therapy.

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

K. Partanen, A. Hemminki, S. Tähtinen, 2013, Clinical Cancer Research.

Immunologic Responses in Patients CD 40 L-Expressing Replicating Adenovirus : Assessment of Safety Oncolytic Immunotherapy of Advanced Solid Tumors with a Updated

K. Partanen, U. Gerdemann, A. Hemminki, 2012 .

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

H. Isoniemi, T. Poussa, T. Alanko, 2011, British Journal of Cancer.

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

H. Joensuu, T. Saarto, T. Alanko, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases

K. Partanen, A. Kangasmäki, T. Joensuu, 2015, Acta oncologica.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.

A. Kangasmäki, M. Ala-opas, A. Hemminki, 2016, Anticancer research.

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report

K. Kairemo, T. Alanko, N. Rasulova, 2014, Asia Oceania journal of nuclear medicine & biology.

The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.

E. Lehtonen, T. Alanko, O. Saksela, 1991, Cell regulation.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

J. Karbach, K. Partanen, N. Linder, 2015, Oncoimmunology.

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.

A. Italiano, K. Yoh, M. Millward, 2021, Cancer treatment and research communications.

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization

J. Karbach, K. Partanen, N. Linder, 2014, Oncoimmunology.

Fibroblast growth factor-mediated stimulation of differentiating teratocarcinoma cells: Evidence for paracine growth regulation

E. Lehtonen, T. Alanko, O. Saksela, 1995 .

FGF-2 inhibits apoptosis in human teratocarcinoma cells during differentiation on collagen substratum.

E. Lehtonen, T. Alanko, O. Saksela, 1996, Experimental cell research.

Development of FGF-dependency in human embryonic carcinoma cells after retinoic acid-induced differentiation.

E. Lehtonen, T. Alanko, O. Saksela, 1994, Developmental biology.

Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

R. Berger, J. Bono, E. Antonarakis, 2019, Journal of Clinical Oncology.

Growth factor effects on cell survival in three-dimensional cultures

T. Alanko, 2000 .

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

FGF‐2 blocks TGF‐β1‐mediated suppression of Bcl‐2 in normal melanocytes

M. Laiho, M. von Willebrand, T. Alanko, 2005, Experimental dermatology.

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

C. Drake, S. Park, E. Antonarakis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.

Jorma Isola, Heikki Joensuu, Vesa Kataja, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

A. Italiano, M. Millward, M. Tanner, 2021, Cancer Immunology, Immunotherapy.

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

J. Karbach, K. Partanen, N. Linder, 2016, Journal of Immunotherapy for Cancer.

An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors.

J. Karbach, K. Partanen, N. Linder, 2015 .

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

J. Koivunen, Jussi Ekström, T. Alanko, 2019, Journal of Cancer Research and Clinical Oncology.

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study

J. Koivunen, P. Vihinen, T. Alanko, 2020, JMIR formative research.

Induction of Proliferation in Isolated Guinea Pig Gastric Epithelium During Restitution After Superficial Injury

T. Paavonen, E. Kivilaakso, T. Alanko, 1998, Digestive Diseases and Sciences.

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study (Preprint)

J. Koivunen, P. Vihinen, T. Alanko, 2020 .

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

L. Montanaro, M. Derenzini, U. Gerdemann, 2012, Cancer research.

Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

T. Pellinen, A. Hemminki, T. Alanko, 2024, Clinical cancer research : an official journal of the American Association for Cancer Research.

611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study

R. Berger, J. Bono, E. Antonarakis, 2021, Annals of Oncology.